Tyra Biosciences, Inc. Research and Development Expense
Tyra Biosciences, Inc. (TYRA) reported Research and Development Expense of $39.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- Tyra Biosciences, Inc. research and development expense for the quarter ending 2026-06-30 was $39.20M, a 61.24% increase year-over-year.
- Tyra Biosciences, Inc. research and development expense for the quarter ending 2026-03-31 was $33.47M, a 34.07% increase year-over-year.
- Tyra Biosciences, Inc. research and development expense for the quarter ending 2025-12-31 was $28.19M, a 27.08% increase year-over-year.
- Tyra Biosciences, Inc. research and development expense for the quarter ending 2025-09-30 was $25.47M, a 12.21% increase year-over-year.
- Tyra Biosciences, Inc. research and development expense for fiscal 2025 was $102.93M, a 28.54% increase from fiscal 2024.
- Tyra Biosciences, Inc. research and development expense for fiscal 2024 was $80.08M, a 28.09% increase from fiscal 2023.
- Tyra Biosciences, Inc. research and development expense for fiscal 2023 was $62.52M, a 45.36% increase from fiscal 2022.
- Tyra Biosciences, Inc. research and development expense for fiscal 2022 was $43.01M, a 108.41% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $39.20M 10-Q · filed 2026-08-04 | $72.67M 10-Q · filed 2026-08-04 | $100.85M derived: sum of 3 quarters · filed 2026-08-04 | $126.32M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $33.47M 10-Q · filed 2026-05-13 | $61.66M derived: sum of 2 quarters · filed 2026-05-13 | $87.13M derived: sum of 3 quarters · filed 2026-05-13 | $111.43M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $28.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $53.66M derived: sum of 2 quarters · filed 2026-03-02 | $77.96M derived: sum of 3 quarters · filed 2026-08-04 | $102.93M 10-K · filed 2026-03-02 |
| 2025-09-30 | $25.47M 10-Q · filed 2025-11-05 | $49.78M derived: sum of 2 quarters · filed 2026-08-04 | $74.74M 10-Q · filed 2025-11-05 | $96.92M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $24.31M 10-Q · filed 2026-08-04 | $49.27M 10-Q · filed 2026-08-04 | $71.45M derived: sum of 3 quarters · filed 2026-08-04 | $94.15M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $24.96M 10-Q · filed 2026-05-13 | $47.14M derived: sum of 2 quarters · filed 2026-05-13 | $69.84M derived: sum of 3 quarters · filed 2026-05-13 | $87.84M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $22.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $44.88M derived: sum of 2 quarters · filed 2026-03-02 | $62.87M derived: sum of 3 quarters · filed 2026-03-02 | $80.08M 10-K · filed 2026-03-02 |
| 2024-09-30 | $22.70M 10-Q · filed 2025-11-05 | $40.69M derived: sum of 2 quarters · filed 2025-11-05 | $57.90M 10-Q · filed 2025-11-05 | $78.57M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $18.00M 10-Q · filed 2025-08-14 | $35.20M 10-Q · filed 2025-08-14 | $55.88M derived: sum of 3 quarters · filed 2025-08-14 | $75.15M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $17.20M 10-Q · filed 2025-05-08 | $37.88M derived: sum of 2 quarters · filed 2025-05-08 | $57.15M derived: sum of 3 quarters · filed 2025-05-08 | $69.31M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $20.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $39.95M derived: sum of 2 quarters · filed 2025-03-27 | $52.11M derived: sum of 3 quarters · filed 2025-03-27 | $62.52M 10-K · filed 2025-03-27 |
| 2023-09-30 | $19.27M 10-Q · filed 2024-11-07 | $31.43M derived: sum of 2 quarters · filed 2024-11-07 | $41.84M 10-Q · filed 2024-11-07 | $52.24M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $12.16M 10-Q · filed 2024-08-07 | $22.57M 10-Q · filed 2024-08-07 | $32.97M derived: sum of 3 quarters · filed 2024-08-07 | $43.88M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $10.41M 10-Q · filed 2024-05-09 | $20.81M derived: sum of 2 quarters · filed 2024-05-09 | $31.72M derived: sum of 3 quarters · filed 2024-05-09 | $43.77M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $10.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $21.32M derived: sum of 2 quarters · filed 2024-03-19 | $33.36M derived: sum of 3 quarters · filed 2024-03-19 | $43.01M 10-K · filed 2024-03-19 |
| 2022-09-30 | $10.91M 10-Q · filed 2023-11-07 | $22.96M derived: sum of 2 quarters · filed 2023-11-07 | $32.61M 10-Q · filed 2023-11-07 | $39.86M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $12.05M 10-Q · filed 2023-08-10 | $21.69M 10-Q · filed 2023-08-10 | $28.94M derived: sum of 3 quarters · filed 2023-08-10 | $34.43M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $9.64M 10-Q · filed 2023-05-04 | $16.89M derived: sum of 2 quarters · filed 2023-05-04 | $22.38M derived: sum of 3 quarters · filed 2023-05-04 | $26.76M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $7.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $12.73M derived: sum of 2 quarters · filed 2023-03-22 | $17.11M derived: sum of 3 quarters · filed 2023-03-22 | $20.64M 10-K · filed 2023-03-22 |
| 2021-09-30 | $5.48M 10-Q · filed 2022-11-03 | $9.87M derived: sum of 2 quarters · filed 2022-11-03 | $13.39M 10-Q · filed 2022-11-03 | $16.32M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $4.38M 10-Q · filed 2022-08-04 | $7.90M 10-Q · filed 2022-08-04 | $10.83M derived: sum of 3 quarters · filed 2022-08-04 | $12.69M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $3.52M 10-Q · filed 2022-05-05 | $6.45M derived: sum of 2 quarters · filed 2022-05-05 | $8.31M derived: sum of 3 quarters · filed 2022-05-05 | |
| 2020-12-31 | $2.93M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $4.79M derived: sum of 2 quarters · filed 2022-03-03 | $7.20M 10-K · filed 2022-03-03 | |
| 2020-09-30 | $1.86M 10-Q · filed 2021-11-03 | $4.28M 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |